German Stem Cell Scientists Develop 3-D “Mini-retinas” –New Hope for Restoring Sight in Patients with Retinal Degeneration Caused by Diabetes and Inherited Disorders.
Breakthrough in Retinal Regeneration Using 3D Organoids
Protocol for 3D Mini-retinas

German researchers have achieved a significant breakthrough in stem cell technology focused on restoring sight through the development of 3D retina organoids. Published in Stem Cell Reports in March, this study leverages the self-organizing properties of stem cells to create complex, multi-cellular tissue structures.
The innovative protocol involves dividing organoids grown from stem cells into three half-moon shaped pieces during early eye development. This technique facilitates the growth of fully functional retinal cells within each segment, including cone photoreceptors crucial for high acuity and color vision. These advancements are particularly promising for patients suffering from retinal degenerative disorders caused by diabetes and inherited conditions.
Advantages of 3D Retinal Organoids

The development process not only enhances the production yield of retinal organoids by up to four times compared to previous methods but also allows for the formation of more realistic tissue structures resembling natural retinal tissue during development.
Applications in Retinal Disease Research
According to senior author Mike Karl from the German Center for Neurodegenerative Diseases (DZNE) and the Center for Regenerative Therapies (CRTD) at Technische Universität Dresden, the versatility of 3D mini-retinas extends beyond replication of retinal tissue. It offers diverse opportunities for studying retinal diseases and potential therapeutic interventions.
Future Directions in Organoid Research
Karl’s team aims to enhance the complexity of mini-retinas by incorporating blood vessels and studying the regeneration capabilities and neural cell functions specific to the human retina. This approach not only furthers understanding of retinal diseases but also holds promise for developing personalized treatments.
Insights and Comparative Studies
Comparative studies between human pluripotent stem cell-derived retina organoids and in vivo mouse retina underscore the potential of this novel organoid protocol to model retinal diseases effectively.
- Published in Corporate News / Blog
Global Stem Cells Group Announces Manufacturing Phase of Progenikine™ SVF Closed System
Global Stem Cells Group has begun the manufacturing phase of Progenikine™, a new SVF closed system kit utilizing EmCyte technology, containing all the elements necessary to process adipose tissue and obtain stromal vascular fraction in a sterile environment.
MIAMI, March 31, 2016—Global Stem Cells Group, Inc. has announced that Progenikine™, its new and approved SVF closed system kit using EmCyte technology, is in the manufacturing phase and will be available to physicians in July 2016. The Progenikine kit contains all the elements necessary to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment.
Adipose derived stem cells (ASCs) are used by physicians for a variety of indications. Most commonly, ASCs are
isolated at the point of care from lipoaspirate (derived from liposuction) tissue as the stromal vascular fraction (SVF), harvested from the patient and immediately administered to the patient as an injection, or used to enrich fat grafts. Isolation of ASCs from adipose tissue is a relatively simple process performed routinely in cell biology laboratories, but isolation at the point of care for immediate clinical administration requires special methodology to prevent contamination, ensure integrity of the clinical procedure, and comply with regulatory requirements.
Developed in conjunction with Patrick Pennie, Emcyte CEO, and and Maritza Novas Director of Research and Development for Global Stem Cells Group, Progenikine
fuses elements from Emcyte systems with the Global Stem cells Group SVF protocols.The kit can provide a low cost, rapid and simple alternative to traditional methods of isolating ASCs, particularly when smaller quantities are needed.
“The Progenikine kit is the newest product designed to help Global Stem Cells Group’s mission to provide accessible products to our member clients, ensuring that more patients will be able to gain access to stem cell therapies,” says Benito Novas, GSCG CEO.
For more information on Global Stems Cell Group, visit the Global Stem Cells Group website,email bnovas(at)stemcellsgroup(dot)com, or call +1 305 560 5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Emcyte:
Fort Myers, Florida-based EmCyte Corporation is a leader in autologous cellular biologics with the GenesisCS Component Concentrating Systems. These systems provide patients with the best opportunity for rapid recovery and provide practitioners with the most advanced clinical point of care experience. EmCyte systems are developed to meet every clinical requirement, giving the physician better clinical choices. EmCyte devices have been independently reviewed and show to produce buffycoat concentrations of 6x to greater than 10x baseline in 7mLs, with yields ranging from 70 percent to greater than 90 percent
EmCyte technology allows for the safe extraction of concentrated platelets and other regenerative cell types from the patient’s own blood. These cells are then re-suspended in a small volume of the patient’s blood plasma and then applied to the treatment site.
###
To view this press release live online, click here
- Published in Press Releases
Our Friend MSCs (Mesenchymal Stem Cells)—Bringing New Life to Old Bones
Understanding MSCs and Their Role in Osteoporosis Treatment
Researchers from the University of Toronto and The Ottawa Hospital have explored the potential of mesenchymal stem cells (MSCs) in treating osteoporosis. MSCs are versatile stromal cells capable of differentiating into bone cells (osteoblasts), cartilage cells (chondrocytes), muscle cells (myocytes), and fat cells (adipocytes).
Research Insights: MSCs Reverse Osteoporosis in Mice

In a groundbreaking study published in Stem Cells Translational Medicine, researchers injected healthy MSCs into mice with osteoporosis. Over six months—a significant period in a mouse’s lifespan—the damaged, brittle bones of the mice were replaced with healthy bone tissue. This restoration underscores the regenerative potential of MSCs in treating bone disorders.
Clinical Applications and Future Directions
This discovery raises hopes for new osteoporosis treatments in humans. Early trials involving elderly patients in the US have shown promising results, with ongoing studies assessing improvements in bone health through biological markers in blood samples.
The Global Impact of Osteoporosis

Globally, over 200 million people suffer from postmenopausal or age-related osteoporosis, leading to approximately 8.9 million bone fractures annually. Current treatments, like Teriparatide, offer temporary relief, highlighting the urgent need for more effective, long-term solutions.
Key Researchers and Publications
Dr. William Stanford, senior scientist at The Ottawa Hospital Research Institute and professor at the University of Ottawa, led the study linking MSC defects to age-related osteoporosis in mice. Co-author Dr. John E. Davies, professor at the University of Toronto, contributed to the study’s publication in Stem Cells Translational Medicine on March 17, 2016.
- Published in Corporate News / Blog
Could stem cells repair the damaged brain in Alzheimer’s?
Stem Cell Therapies: A Potential Cure for Alzheimer’s?
Understanding Alzheimer’s Disease

Alzheimer’s disease is a progressive and irreversible brain disorder characterized by symptoms such as disorientation regarding time and place, changes in mood, personality and behavior, memory loss, difficulty solving problems or planning, and difficulty writing or performing other routine tasks. This condition primarily affects people aged 70 years and above, with a higher prevalence in women. It is the main risk factor for dementia among the elderly.
Limitations of Conventional Treatments

Currently, there is no known cure for Alzheimer’s. Conventional treatments, including both drug-based and non-drug strategies, may help with cognitive and behavioral symptoms but have little to no effect on the disease’s long-term progression. Medications available today cannot stop Alzheimer’s from progressing; they can only temporarily lessen symptoms like confusion and memory loss.
Exploring Stem Cell Therapies
Due to the limitations of conventional treatments, scientists are exploring the possibilities of stem cell therapies in Alzheimer’s treatments. Stem cells have the potential to develop new neurons, replace dead and damaged cells, and deliver neurotrophins to support neuron growth and survival.
Challenges in Developing Stem Cell Therapies
- Transplanting Neural Stem Cells:
- Theoretically, transplanting neural stem cells into the patient’s brain could generate healthy new neurons. However, it remains unclear whether the brain would integrate the transplanted cells effectively and if they could travel to the damaged areas.
- Producing the different types of neurons needed to replace the damaged cells and stimulating the renewal of lost connections between neural cells pose significant challenges.
- Delivering Neurotrophins:
- Neurotrophin proteins support neuron growth and survival, but Alzheimer’s patients produce insufficient amounts. Neural stem cells can produce these proteins, and studies in mice have shown some improvements in memory when treated with stem cells.
- Mesenchymal Stem Cells:
- Mesenchymal stem cells may exert anti-inflammatory effects and help ameliorate Alzheimer’s symptoms. However, there is currently no study proving their safety or effectiveness for this condition.
Research and Studies
Despite the high failure rate of clinical trials and studies on Alzheimer’s treatment, stem cells may still be valuable for studying the behavior of brain cells damaged by the condition. They can also be used for testing various therapeutic approaches and predicting which treatments might help Alzheimer’s patients.
- Induced Pluripotent Stem Cells (iPSC):
- Researchers from the Harvard Stem Cells Institute reprogrammed skin cells from Alzheimer’s patients to create iPSCs. These cells, grown in lab conditions, released the same proteins that form plaques in Alzheimer’s patients. This advancement allows scientists to study Alzheimer’s-affected cells and test new remedies.
- Neuronal Cell Conversion:
- Asian scientists turned human fibroblasts into neuronal cells using a chemical cocktail of small molecules. These findings provide an alternative strategy for modeling neurodegenerative disorders and may play a crucial role in identifying new stem cell-based treatments.
Conclusion
Stem cell therapies hold promise for developing new treatments for Alzheimer’s disease. While many challenges and uncertainties remain, ongoing research offers hope for understanding and potentially curing this debilitating condition.
References
- Published in Corporate News / Blog
New Stem Cell Research Shows Promising Results for Muscular Dystrophy
Understanding Muscular Dystrophy
Muscular dystrophy (MD) encompasses a group of genetic disorders that cause progressive muscle weakness and loss of muscle mass. These disorders, affecting primarily skeletal muscles, can also impact respiratory and swallowing muscles, leading to severe disability over time.
Types and Impact of Muscular Dystrophy

There are various types of muscular dystrophy, with Duchenne muscular dystrophy (DMD) being the most severe and common form, primarily affecting young boys. DMD is characterized by a genetic mutation that prevents the production of dystrophin, a crucial protein for muscle function. This deficiency leads to progressive muscle degeneration, loss of mobility, and, in many cases, premature death.
Current Treatments and Limitations
Currently, there is no cure for DMD. Treatment focuses on managing symptoms and slowing disease progression through therapies like physiotherapy and steroids. However, these treatments have limitations and often come with significant side effects.

Potential of Stem Cell Therapies for Muscular Dystrophy
Regeneration with Stem Cells
Stem cell research offers promising avenues for treating muscular dystrophy by targeting muscle regeneration. Studies have shown that stem cells isolated from muscle tissue, bone marrow, and blood vessels can potentially regenerate dystrophin-deficient muscle fibers in animal models.
Experimental Success with Stem Cells
Recent studies have demonstrated encouraging results in animal models of DMD. Researchers have successfully restored mobility in dogs and improved muscle function in mice by transplanting stem cells. These studies suggest that stem cells could potentially replace damaged muscle tissue and restore muscle function.
Combining Stem Cell and Gene Therapies
Emerging research also explores combining stem cell therapies with genetic correction techniques. This approach aims to correct the genetic defect responsible for DMD and stimulate muscle regeneration simultaneously, showing promising outcomes in preclinical studies.
Future Directions and Research
While the application of stem cell therapies for DMD in humans is still in its early stages, ongoing research holds significant promise. Future studies will focus on optimizing stem cell treatments, enhancing their safety and efficacy, and ultimately translating these findings into viable therapies for patients with muscular dystrophy.
Conclusion
Stem cell research represents a beacon of hope for advancing treatment options for muscular dystrophy, particularly DMD. As research progresses and clinical trials continue, the potential of stem cells to regenerate muscle tissue and improve quality of life for patients with muscular dystrophy becomes increasingly promising.
References:
- http://www.mayoclinic.org/diseases-conditions/muscular-dystrophy/basics/definition/con-20021240
- http://www.eurostemcell.org/factsheet/muscular-dystrophy-how-could-stem-cells-help
- https://www.mda.org/disease/duchenne-muscular-dystrophy/research
- http://quest.mda.org/article/scientists-bullish-stem-cells-muscle-repair
- http://hsci.harvard.edu/stem-cells-used-treat-muscular-dystrophy-mice
- https://med.stanford.edu/news/all-news/2014/12/stem-cells-faulty-in-duchenne-muscular-dystrophy.html
- Published in Corporate News / Blog
Global Stem Cells Group to Hold Intensive, Two-day Training Course on Stem Cell Harvesting, Isolation and Re-integration Sept. 27 and 28 Following International Symposium
Global Stem Cells Group announced plans to hold a two-day, hands-on intensive stem cell training course at the Servet Clinic following the First International Symposium on Stem Cells and Regenerative Medicine in Santiago Chile, Sept. 26, 27 and 28, 2014.
Global Stem Cells Group, its subsidiary Stem Cell Training, Inc. and Bioheart, Inc. have announced plans to conduct a two-day, hands-on intensive stem cell training course at the Servet CordónVida Clinic Sept. 27 and 28 in Santiago, Chile. The “Adipose Derived Harvesting, Isolation and Re-integration Training Course,” will follow the Global Stem Cells Group First International Symposium on Stem Cells and Regenerative Medicine at the Santiago InterContinental Hotel Sept. 26, 2014.
Global Stem Cells Group and the Servet CordónVida Stem Cell Bank Clinic of Chile are co-organizing the symposium, designed to initiate a dialogue between researchers and practitioners and share the expertise of some of the world’s leading experts on stem cell research and therapies.
Servet CordónVida is a private umbilical cord blood bank that harvests and stores the hematopoietic-rich blood stem cells found in all newborns’ umbilical cords after birth. The hematopoietic tissue is responsible for the renewal of all components of the blood (hematopoiesis) and has the ability to regenerate bone marrow and restore depressed immune systems.
Umbilical (UCB) stem cells offer a wealth of therapeutic potential because they are up to 10 times more concentrated than bone marrow stem cells. In addition, UCB cells have a generous proliferative capacity with therapeutic potential that is very similar to embryonic stem cells, without the ethical debate associated with embryonic stem cell research and use.
UCB cells are the purest adult stem cells available, coming from newborns who have not been exposed to disease or external damage. Many parents today are utilizing cord banks like Servet CordónVida to store their newborn’s UCB cells safely for future medicinal use if the need arises.
Global Stem Cells Group and Servet CordónVida represent a growing global community of committed stem cell researchers, practitioners and investors whose enthusiasm is a direct result of the hundreds of diseases and injuries that stem cell therapies are curing every day. Global Stem Cell Group’s First International Symposium on Stem Cell Research and Regenerative Medicine will host experts from the U.S., Mexico, Greece, Hong Kong and other regions around the globe who will speak on the future of regenerative medicine and share experiences in their field of specialty. The Global Stem Cells Group is hoping the symposium will open lines of communication and cooperation, explore new and exciting techniques in stem cell therapies, and create an environment of education and learning.
- Published in Press Releases







